Accessibility Menu
Context Therapeutics logo

Context Therapeutics(NASDAQ) CNTX

Current Price$0.61
Market Cap$56.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-88%
5 YearN/A
1 Year-27%
1 Month+7%
Context Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.612026-07-24
Context Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.35%USD 0.602026-07-17
1 month+6.61%USD 0.582026-06-24
3 month-72.83%USD 2.262026-04-24
Year to date-58.22%USD 1.472025-12-31
1 year-26.96%USD 0.842025-07-24
3 year-42.07%USD 1.062023-07-25
Since inception-87.96%USD 5.102021-10-20

Context Therapeutics Financials at a Glance

Market Cap

$56.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.23M

EPS (TTM)

-$0.43

P/E Ratio

-1.44

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$0.61

Volume

44,668

Open

$0.60

Previous Close

$0.61

Daily Range

$0.56 - $0.61

52-Week Range

$0.55 - $3.62

Estimated Earnings Date

Aug 5, 2026

CNTX News

No articles available.

CNTX: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Context Therapeutics

Context helps the body's immune system find and destroy cancer cells. Its drugs act as a bridge between defense cells and tumors. This helps treat serious illnesses like ovarian or lung cancer.

Targeting Tumors with Antibodies

  • CTIM-76: Antibody targeting solid tumors in ovarian and testicular cancer; currently in Phase 1 clinical trials to test safety in humans.
  • CT-95: Molecule designed to guide immune cells toward tumors that produce a specific protein; clinical testing in patients began in April 2025.
  • CT-202: Treatment targeting a protein found in bladder and lung cancers; human testing is expected to begin in the third quarter of 2026.

Key Partnerships and Asset Acquisitions

  • Entered a licensing deal with Integral Molecular in April 2021 to develop antibodies that trigger immune responses against cancer cells.
  • Acquired the rights to CT-95 from Link in July 2024 to expand the portfolio of clinical-stage products.
  • Signed a worldwide license agreement with BioAtla in September 2024 to develop and commercialize the CT-202 antibody program.
  • Partnered with Lonza in 2022 and 2025 to secure manufacturing services for the company's lead drug candidates.

Specialized Immune System Strategies

Context focuses on bispecific antibodies, which are drugs that can attach to two different targets at once. This design allows the drug to grab a cancer cell with one arm and an immune cell with the other, bringing them together so the body can fight the tumor.

Measuring the Financial Burn

  • Operating loss reached $9.3 million in Q1 2026, deepening by 69% from the previous year.
  • Net loss worsened to $8.7 million for the period ended March 31, 2026, an 89.6% increase year-over-year.
  • Cash and cash equivalents totaled $54.5 million as of March 31, 2026.
  • Free cash flow was negative $11.5 million in Q1 2026, worsening by 126.5% compared to Q1 2025.

The Evolution of Context

Context has transitioned from an early researcher into a clinical-stage developer with three active antibody programs. The company relies on strategic licensing and manufacturing partnerships to advance its pipeline toward potential regulatory approval.

AI Generated • May 14, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

15

CEO

Martin A. Lehr, MA

Website

www.contexttherapeutics.com

Headquarters

Philadelphia, PA 19103, US

CNTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-59.95%

Return on Capital

-65.53%

Return on Assets

-68.34%

Earnings Yield

-69.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$56.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

91.88M

Volume

44.67K

Avg. Volume

2.29M

Financials (TTM)

Gross Profit

-$40.17K

Operating Income

-$43.52M

EBITDA

-$40.18M

Operating Cash Flow

-$32.79M

Capital Expenditure

-$37.26K

Free Cash Flow

-$32.82M

Cash & ST Invst.

$54.53M

Total Debt

$282.42K

Context Therapeutics Performance Analysis

Context Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Context Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Context Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.9341.9%
20232023-12-31USD -1.5061.5%
20242024-12-31USD -0.46-69.5%
20252025-12-31USD -0.38-17.0%
Context Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-85.4%
Q32025-09-30-7.9%
Q42025-12-31-40.0%
Q12026-03-3134.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$36.11K

N/A

Gross Margin

0.00%

N/A

Market Cap

$56.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.76M

N/A

Employees

15

N/A

Net Income

-$8.68M

-89.6%

EBITDA

-$8.64M

-89.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$54.53M

-39.0%

Total Debt

$282.42K

+45.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$122.37K

+48.1%

Short Term Debt

$160.06K

+44.1%

Return on Assets

-68.34%

N/A

Return on Invested Capital

-83.17%

N/A

Free Cash Flow

-$11.47M

-126.5%

Operating Cash Flow

-$11.43M

-127.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLNNClene Inc.
$5.39-1.64%
IMAImageneBio Inc
$5.59+0.36%
KLRSKalaris Therapeutics Inc
$3.73-4.85%
IFRXInflaRx N.V.
$1.74+0.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About CNTX

What is the current price of Context Therapeutics?

Context Therapeutics is trading at $0.61 per share.

What is the 52-week range for Context Therapeutics?

Over the past 52 weeks, Context Therapeutics has traded between $0.55 and $3.62.

How much debt does Context Therapeutics have?

As of the most recent reporting period, Context Therapeutics reported total debt of $282.42K.

How much cash does Context Therapeutics have on hand?

Context Therapeutics reported $54.53M in cash and cash equivalents in its most recent financial results.

What is Context Therapeutics’s dividend yield?

Context Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services